drugset / Trial / NCT00266227
A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy of retreatment with rituximab in subjects with active rheumatoid arthritis (RA) who are receiving Methotrexate (MTX).
Timeline
- Start
- 2006-01
- Primary completion
- 2007-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 1000 mg | Intravenous |
| Background | Methotrexate | Small molecule | 10 mg | Oral |
| Background | Methotrexate | Small molecule | 25 mg | Oral |
| Background | folic acid | Small molecule | — | Intravenous |